Skip to content
DataLookout
Menu

NCT06920004

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

StatusRecruiting
PhasePhase 3
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 107 to 109
  2. Minor Trial sites expanded: 101 → 107 locations
  3. Minor Study sites: 102 to 103
  4. Minor Study sites: 101 to 102
  5. Minor Trial sites expanded: 95 → 101 locations
    • Site details revised at 14 of 101 sites
  6. Minor Study sites: 95 to 101
  7. Notable Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 89 → 95 locations
    • Secondary endpoints: details revised at 15 of 25 entries
  8. Minor Trial sites expanded: 82 → 89 locationsv12
  9. Minor Trial sites expanded: 75 → 82 locationsv11
  10. Minor Study sites: 73 to 75v10
  11. Minor Trial sites expanded: 47 → 73 locationsv9
  12. Minor Study sites: 46 to 47v8
  13. Minor Study sites: 27 to 46v7
  14. Minor Study sites: 10 to 27v6
  15. Minor Study sites: 6 to 10v5
  16. Minor Study sites: 4 to 6v4
  17. Minor Study sites: 1 to 4v3
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: May 2027 to Sep 2027
    • Study completion date: May 2030 to Sep 2030
    • Start date changed from estimate of May 2025 to Aug 22, 2025
    v2
  19. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Reduction of ≥1 point compared with baseline in aINCAT score at week 24
Timeframe: up to 24 weeks

Secondary (25)

Change from baseline in I-RODS centile points score at week 24
Change from baseline in MRC-SS at week 24
Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24
Time to reduction of ≥1 point from baseline in aINCAT score
Change from baseline in TUG at week 24
Show 20 moreShow less
Time to increase of ≥1 point compared with baseline in aINCAT score
Change from baseline in grip strength (3-day moving average) of both hands over time
Change from baseline in grip strength (daily average) for both hands
Change from baseline in MRC-SS over time
Change from baseline in aINCAT over time
Change from baseline in EQ-5D-5L over time
Change from baseline in RT-FSS over time
Change from baseline in SF-12 over time
Change from baseline in BPI-SF over time
PGI-S values over time
PGI-C values over time
Values for work-related and household chore activities of the HRPQ
Percentage of scheduled hours lost in total (absenteeism+ presenteeism)
Change from baseline in I-RODS centile points score over time
Change from baseline in TUG over time
Incidence of antidrug antibodies against empasiprubart in serum
Incidence of neutralizing antibodies against empasiprubart in serum
Incidence of (serious) adverse events
Percentage change from baseline in free C2 and total C2 over time
Serum concentrations of empasiprubart over time

Arms and interventions

Part A - empasiprubart + IVIg-placeboExperimental

During Part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm.

Part A - IVIg + empasiprubart-placeboActive comparator

During Part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm.

Part B - empasiprubartExperimental

After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg). Participants from the empasiprubart + IVIg- placebo arm in Part A will receive empasiprubart placebo once to maintain the blind of Part A.

Biologicals: empasiprubart, IVIg

Other: empasiprubart-placebo, IVIg-placebo

Sites

109 sites in 31 countries

United States 19, Poland 12, Japan 10, France 7, Italy 7, Brazil 4, Romania 4, South Korea 4, Spain 4, Canada 3, Colombia 3, Israel 3, United Kingdom 3, Argentina 2, Austria 2, Estonia 2, Germany 2, Greece 2, Serbia 2, Slovenia 2, Turkey (Türkiye) 2, Australia 1, Czechia 1, Hungary 1, Netherlands 1, Norway 1, Portugal 1, Singapore 1, Slovakia 1, Sweden 1, Switzerland 1